HomeCompareLZAGF vs DIVO

LZAGF vs DIVO: Dividend Comparison 2026

LZAGF yields 1.10% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LZAGF wins by $13.8K in total portfolio value· pulled ahead in Year 8
10 years
LZAGF
LZAGF
● Live price
1.10%
Share price
$650.29
Annual div
$7.14
5Y div CAGR
45.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$8,733.09
Full LZAGF calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — LZAGF vs DIVO

📍 LZAGF pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLZAGFDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LZAGF + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LZAGF pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LZAGF
Annual income on $10K today (after 15% tax)
$93.36/yr
After 10yr DRIP, annual income (after tax)
$7,423.13/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, LZAGF beats the other by $6,588.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LZAGF + DIVO for your $10,000?

LZAGF: 50%DIVO: 50%
100% DIVO50/50100% LZAGF
Portfolio after 10yr
$37.6K
Annual income
$4,857.39/yr
Blended yield
12.91%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LZAGF buys
0
DIVO buys
0
No recent congressional trades found for LZAGF or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLZAGFDIVO
Forward yield1.10%6.49%
Annual dividend / share$7.14$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR45.9%0%
Portfolio after 10y$44.5K$30.7K
Annual income after 10y$8,733.09$981.68
Total dividends collected$22.1K$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: LZAGF vs DIVO ($10,000, DRIP)

YearLZAGF PortfolioLZAGF Income/yrDIVO PortfolioDIVO Income/yrGap
1$10,860$160.25$11,349$649.42$489.00DIVO
2$11,858$237.31$12,833$688.83$975.00DIVO
3$13,041$353.30$14,459$727.90$1.4KDIVO
4$14,484$529.82$16,238$766.49$1.8KDIVO
5$16,300$802.36$18,179$804.47$1.9KDIVO
6$18,672$1,231.24$20,293$841.71$1.6KDIVO
7$21,903$1,923.20$22,591$878.14$688.00DIVO
8← crossover$26,512$3,076.05$25,087$913.65+$1.4KLZAGF
9$33,445$5,077.02$27,791$948.18+$5.7KLZAGF
10$44,519$8,733.09$30,718$981.68+$13.8KLZAGF

LZAGF vs DIVO: Complete Analysis 2026

LZAGFStock

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Full LZAGF Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this LZAGF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LZAGF vs SCHDLZAGF vs JEPILZAGF vs OLZAGF vs KOLZAGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.